EXEL · Exelixis, Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Diluted EPS non-GAAP | $0.91 | Q2 2026 | — |
|
|
|||
| Non-GAAP net income non-GAAP | $237.1M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP net income 212.05M
+12.34M Stock-based compensation - research and development
+20.22M Stock-based compensation - selling, general and administrative
-7.51M Income tax effect of the above adjustments
= Non-GAAP net income 237.1M
|
|||
| Stock Repurchase Program | $750M | May 2026 | — |
| CABOMETYX Net Product Revenues | $2.11B | Fiscal Year 2025 | — |
| Cabozantinib Franchise Net Product Revenues | $2.12B | Fiscal Year 2025 | — |
| COMETRIQ Net Product Revenues | $9.4M | Fiscal Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EXEL
this stock
Exelixis, Inc.
|
$12.70B | +16.9% | +136.3% | 16.1 | 11.6% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EXEL | -5.2% | -8.4% | +16.4% | -3.4% | +16.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -5.6% | -12.8% | +2.7% | -7.3% | +3.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.